58: Acute Quality of Life Changes after Stereotactic Ablative Radiotherapy for Liver Metastasis: A Prospective Cohort Analysis  by Helou, Joelle et al.
CARO 2016                                                                                                                                                                  S23 
_________________________________________________________________________________________________________ 
factors and systems engineering. Through the principles of 
human factors and system engineering, this study seeks to 
understand the relationship of radiation therapy associated 
hardware and software incidents, practitioners, their 
environment, and radiation technology. 
Methods and Materials: A retrospective analysis of incidents 
occurring from April 2013 September 2015 within a major 
metropolitan radiation therapy centre was performed. Radiation 
therapy (RT) related incidents were analyzed using two 
frameworks. Framework I classified incident types as software, 
hardware, or not applicable. Framework II applied the Human 
Factor Analysis and Classification System (HFACS), which was 
used to determine human and systematic attributes to incident 
causation. 
Results: One hundred and seventy-six incidents were identified 
to be RT-related. The application of Framework I indicated 
44.89% and 15.34% involved the use of RT software and hardware 
respectively. A thematic analysis was completed using 
Framework II in relation to the classifications within Framework 
I. An examination of the major classes of software incidents 
showed, 26.70% of the total incidents were software 
transcription-related. A review of the major classes of hardware 
incidents identified 9.09% of total incidents were due to fault of 
the RT device and 5.11% were attributable to operator error. 
Conclusions: The addition of new technology and practices has 
the benefit of improved outcomes for patients. However, it also 
serves as a double edged sword that may potentially increase the 
risk of medical error and patient harm. Applying the principles 
of human factors and systems engineering provides an 
opportunity to identify incidents and leverage software and 
hardware design to potentially mitigate these errors, ultimately 
enhancing patient safety and quality of care. 
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Purpose: The use of stereotactic ablative radiotherapy (SABR) to 
treat metastatic disease is increasing. There is a paucity of 
prospective quality of life (QoL) data published for liver SABR. 
Moreover reported series often include hepatocellular-
carcinoma. Herein we report QoL after SABR in patients with 
liver metastases (LM). 
Methods and Materials: A single-institution prospective cohort 
study was undertaken to measure the acute changes in QoL after 
SABR. Patients with Child-Pugh A liver function, any solid primary 
tumour with 1-3 LM treated with SABR were eligible. Doses of 30-
60 Gy in 3-5 fractions were delivered. Indications of SABR 
included oligometastases and oligoprogression. Prospective QoL 
was measured using the European Organisation for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 
15 Palliative (QLQ-C15) and the EORTC QLQ–liver metastases 
(QLQ-LM21) validated questionnaires at baseline, 1st week of 
treatment, last day of treatment, then one, six and 12 weeks 
after treatment completion. In addition the functional living 
index-emesis (FLIE) was collected at baseline, first week of 
treatment, last day and one week after completion. Univariable 
linear mixed modelling was performed to assess changes of QoL 
over time. Multivariable linear mixed modelling was performed 
to determine predictors of QoL changes after adjusting for time. 
A minimally important difference (MID) in QoL was defined as a 
change of _10 points compared to baseline for each follow up 
visit with ≥ 10-point decrease representing worse QoL. A two-
tailed p-value ≤ 0.05 was considered statistically significant. 
Results: Sixty patients (32 males) were included. Mean age at 
time of treatment was 67 ± 13 years. Median BED10 was 100 Gy 
(58-180). The most common primary cancer was colorectal in 42% 
of the patients followed by other gastro-intestinal malignancies 
in 17% and breast in 15%. Oligometastasis was the treatment 
indication in 55% of patients. Actuarial overall survival at one 
year was 79%. The global health score measured by QLQ-C15 was 
significantly worse at treatment completion (p = 0.001), 1w (p = 
0.003) and 6w (p = 0.002) after SABR but recovered by three 
months (p = 0.124). Nausea, constipation and fatigue were also 
worse at treatment completion (p < 0.05) but recovered one and 
six weeks after treatment. The FLIE questionnaire showed 
consistent findings for nausea with significant deterioration at 
the end of treatment (p < 0.001). The majority of patients 
reported stable or better QoL at three months for all domains in 
the three questionnaires. On multivariable analysis, uninvolved 
liver was a significant predictor of worse fatigue (p = 0.009) and 
appetite (p = 0.004). Duodenum max dose was a predictor of 
constipation (p = 0.026). 
Conclusions: SABR offers a non-invasive mean of ablating liver 
metastases with minimal impact on QoL. Our data suggests that 
some dosimetric parameters are predictors of worse QOL 
outcome. Longer follow up and efficacy data are needed.  
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Purpose:  Anal canal cancer (ACC) and associated treatment can 
adversely impact quality of life, with bowel control and function 
being key considerations. Standard treatment for localized ACC 
consists of combined chemoradiotherapy (CRT). Previous studies 
examining treatment-related late bowel toxicity have not 
adequately assessed baseline function, and any bowel 
dysfunction is often attributed to previous treatment. In this 
single-institution study, we aimed to evaluate patient self-
assessed bowel function and associated symptoms at baseline 
and after radical CRT. 
Methods and Materials: Fifty-four patients with ACC scheduled 
for radical CRT with mitomycin C and 5-fluorouracil were 
recruited. Median patient age was 57 (range 37-83); 36 (66.7%) 
were female; 26 (48.1%) had AJCC Stage II disease, 9 (18.5%) had 
Stage IIIA, and 19 (35.2%) Stage IIIB. Patients completed the 
European Organisation for Research and Treatment of Cancer 
(EORTC) QLQ-C30 and QLQ-CR29 quality of life questionnaires at 
baseline, midpoint and end of CRT, at six and 12 weeks, and six, 
nine, 12, 24, and 36 months post-completion of CRT. Patients 
scored problems of leakage, constipation, diarrhea, stool 
frequency, flatulence, and embarrassment on a scale from 1-4 
indicating the degree of the problem, with a score of 1 
representing “not at all’, and 4 representing “very much”. 
Patient scores were compiled for each time point and compared 
(Fisher’s exact test). 
Results: At baseline, 9.8% of patients had leakage scores of 3-4, 
compared with 11.1% 12 months post-CRT (p = 1.0). 13.4% had 
constipation scores of 3-4 at baseline, compared with 5.3% at 12 
months (p = 0.29). 3.8% had diarrhea scores of 3-4 at baseline, 
compared with 15.8% at 12 months (p = 0.066). 17.7% had stool 
frequency scores of 3-4 at baseline, compared with 19.4% at 12 
months (p = 1.0). 17.7% had flatulence scores of 3-4 at baseline, 
compared with 19.4% at 12 months (p = 1.0). Finally, 
embarrassment scores of 3-4 were reported by 13.7% of patients 
at baseline compared with 11.1% of patients at 12 months (p = 
1.0). At a median follow up time of 26.6 months (range 0-66.4), 
nine patients (16.7%) had a colostomy, 10 (18.5%) had disease 
recurrence, and seven (13.0%) had died. 
Conclusions: In our population, bowel function including fecal 
incontinence, stool frequency, flatulence, and embarrassment 
were comparable 12 months after completion of CRT compared 
with baseline. Diarrhea increased over this time period, while 
constipation decreased, although not reaching statistical 
